Q2
ANTX — Q2 2026 Financial Report Analysis
AN2 Therapeutics' Q2 2026 net loss widened to $8.2M from $6.5M as NIAID cost reimbursement fell from $3.7M to $0.4M, while a $40M March private placement lifted cash to $79.9M ahead of three planned Phase 2 trials.